The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

Inhaled β2-adrenoceptor agonists are by far the most effective and safe bronchodilators
currently available. They have not been surpassed by any other bronchodilating principle …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

Regular treatment with both long-and short-acting β 2-agonists results in tolerance to their
bronchoprotective effects, although the relevance of this phenomenon in terms of long term …

β2-adrenoceptor agonists are the first-line treatment of asthma and chronic obstructive
pulmonary disease (COPD), in which a short-acting β2-adrenoceptor agonist is used as …

New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear
in several European countries for treatment of asthma. This review examines currently …

Conventional low doses of inhaled beta 2‐adrenoceptor agonists produce effective
bronchodilation without systemic effects. Higher doses of inhaled beta 2‐adrenoceptor …

BACKGROUND Despite widespread use of adrenergic agents in the management of
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

β2-adrenoceptor agonists are the mainstay for the acute symptomatic treatment of asthma
and provide effective bronchoprotection to a wide range of bronchoconstrictor agents …